SARASOTA, Fla., July 11, 2014 /PRNewswire/ -- Rock Creek
Pharmaceuticals, Inc. (NASDAQ: RCPI), an emerging biotechnology
company, today announced that the Food and Drug Administration
("FDA"), has notified the Company that the agency will provide
comments on RCP's Investigational New Drug ("IND") application
before granting the Company permission to start its clinical trial
in the US.
Dr. Chris Chapman, RCP's
President, commented, "We appreciate the agency's review and
comments on our IND. When we receive the agency's official comments
and/or recommendations, we will respond expeditiously. We look
forward to moving this important product through the regulatory
process."
Certain statements contained in this release constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements identified by words such as
"believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The
statements in this release are based upon the current beliefs and
expectations of our company's management and are subject to
significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements. Numerous factors
could cause or contribute to such differences, including, but not
limited to, results of clinical trials and/or other studies, the
challenges inherent in new product development initiatives,
including the continued development and market acceptance of our
nutraceutical dietary supplements products, the effect of any
competitive products, our ability to license and protect our
intellectual property, our ability to raise additional capital in
the future that is necessary to maintain our business, changes in
government policy and/or regulation, potential litigation by or
against us, any governmental review of our products or practices
and the outcome of the ongoing investigations as well as other
risks discussed from time to time in our filings with the
Securities and Exchange Commission, including, without limitation,
our annual report on Form 10-K for the fiscal year ended
December 31, 2013 filed on
March 17, 2014. We undertake no
duty to update any forward-looking statement or any information
contained in this press release or in other public disclosures at
any time.
About Rock Creek Pharmaceuticals, Inc.
Rock Creek Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the discovery, development and commercialization of new
drugs, formulations and compounds that provide therapies for
inflammatory conditions, clinical immunology, neurological disease
and behavioral health. Additionally, through its subsidiary
RCP Development, the Company is engaged in the manufacturing and
sale of nutraceutical dietary supplements designed to promote
maintenance of a healthy metabolism and lifestyle.
For more information, visit: http://www.rockcreekpharma.com
Logo - http://photos.prnewswire.com/prnh/20140711/126408
CONTACT:
Ted Jenkins
Vice President, Corporate Strategy, Development, Investor
Relations
Rock Creek Pharmaceuticals
tjenkins@rockcreekpharma.com
SOURCE Rock Creek Pharmaceuticals, Inc.